Midwest Products & Engineering Acquires Racine Metal Fab

Metal Stamping and Fabrication Experts to Enhance MPE's Components Solutions

Midwest Products & Engineering (MPE-INC), a leading design and contract manufacturer to medical and technology OEMs, today announced its acquisition of Racine Metal Fab (RMF), a leader in the fabrication of highly aesthetic and complex precision sheet metal components and sub-assemblies.

“I could not be more pleased with the strategic fit, synergy and cultural compatibility with MPE. My excitement resides in the continued growth of the company and what it means for everyone at RMF including our employees, customers, suppliers and community.”

Kim Nichols, CEO of Racine Metal-Fab

For over 50 years RMF has steadily evolved as a highly respected fabricator known for short lead times and cost efficient solutions. Their core expertise in stamping, rolling, laser cutting, forming, fastening, welding and assembly enhances MPE’s vertically integrated design and contract manufacturing business.

“RMF brings to MPE innovation and core competence in high cosmetic light gauge stamping and fabrication technologies that are integral to the evolving needs of our customers. RMF’s business aligns with MPE as we continue to help original equipment manufacturers accelerate time to market at a lower total cost of ownership.”

MPE President and CEO Hank Koh

Racine Metal Fab provides customers with a one-stop-shop for their metal fabrication needs specializing in light gauge materials, soft and hard tooling design as well as assembly and logistics services which will further enhance MPE’s Concept to Completion model.

For more than 40 years, MPE has successfully serviced an impressive list of blue-chip medical device and technology OEMs delivering operational efficiencies, improving the total cost of ownership while meeting or exceeding market requirements the first time. The acquisition of RMF will help MPE as they continue to expand its capabilities and grow as a global leader in the Medical and Technology OEM market.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”